Skip to main content

Advertisement

SpringerLink
Log in

The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis

  • Viewpoint
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

The purpose of the present study was to examine of the current role of bone turnover markers (BTMs) in the management of osteoporosis. Perusal of the literature examines the available evidence for the utility of BTMs for decision to treat and for the monitoring of treatment for osteoporosis. There is no evidence for the use of BTMs for fracture risk calculation, decision to treat or for treatment selection. A very abnormal BTM value may be a clue to the presence of bone pathology other than uncomplicated osteoporosis. Whilst changes to BTMs following various osteoporosis treatments are well defined, their utility in monitoring individual patients has been less well established. Some fracture outcome-based data exist for the use of u-NTX target of <21 nmol BCE/mmol for antiresorptive therapy; the equivalent s-CTX level is ~250 ng/L. Suboptimal BTM response to treatment may indicate non-compliance or the presence of secondary causes of osteoporosis which may need addressing. Studies are needed to establish treatment targets based on fracture outcomes for commonly used BTMs for each established osteoporosis therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. P.D. Delmas, R. Eastell, P. Garnero, M.J. Seibel, J. Stepan, The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11, 2–17 (2000)

    Article  CAS  Google Scholar 

  2. T. Cundy, I.R. Reid, Paget’s disease of bone. Clin. Biochem. 45(1–2), 43–48 (2012)

    Article  CAS  PubMed  Google Scholar 

  3. S. Vasikaran, R. Eastell, O. Bruyère, A.J. Foldes, P. Garnero, A. Griesmacher, M. McClung, H.A. Morris, S. Silverman, T. Trenti, D.A. Wahl, C. Cooper, J.A. Kanis, IOF-IFCC Bone Marker Standards Working Group, Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos. Int. 22, 391–420 (2011)

    Article  CAS  PubMed  Google Scholar 

  4. D. Bauer, J. Krege, N. Lane, E. Leary, C. Libanati, P. Miller, G. Myers, S. Silverman, H.W. Vesper, D. Lee, M. Payette, S. Randall, National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos. Int. 23, 2425–2433 (2012)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. P. Garnero, E. Sornay-Rendu, B. Claustra, P.D. Delmas, Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J. Bone. Miner. Res. 15(8), 1526–1536 (2000)

    Article  CAS  PubMed  Google Scholar 

  6. P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, C. Muller, C. Cormier, G. Bréart, P.J. Meunier, P.D. Delmas, Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J. Bone Miner. Res. 11(10), 1531–1538 (1996)

    Article  CAS  PubMed  Google Scholar 

  7. H. Johansson, A. Odén, J.A. Kanis, E.V. McCloskey, H.A. Morris, C. Cooper, S. Vasikaran, IFCC-IOF Joint Working Group on Standardisation of Biochemical Markers of Bone Turnover, A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif. Tissue Int. 94(5), 560–567 (2014)

    Article  CAS  PubMed  Google Scholar 

  8. J.A. Kanis, O. Johnell, A. Oden, H. Johansson, E. McCloskey, FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385–397 (2008)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. I. Baxter, A. Rogers, R. Eastell, N. Peel, Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporos. Int. 24(3), 941–947 (2013)

    Article  CAS  PubMed  Google Scholar 

  10. D.C. Bauer, P. Garnero, M.C. Hochberg, A. Santora, P. Delmas, S.K. Ewing, D.M. Black, Fracture Intervention Research Group, Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J. Bone Miner. Res. 21(2), 292–299 (2006)

    Article  CAS  PubMed  Google Scholar 

  11. P.D. Delmas, A.A. Licata, J.Y. Reginster, G.G. Crans, P. Chen, D.A. Misurski, R.B. Wagman, B.H. Mitlak, Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover. Bone 39(2), 237–243 (2006)

    Article  CAS  PubMed  Google Scholar 

  12. J.A. Clowes, N.F. Peel, R. Eastell, The impact of monitoring on adherence and persistence with antiresorptive treatment for Osteoporos Int postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 89, 1117–1123 (2004)

    Article  CAS  PubMed  Google Scholar 

  13. P.D. Delmas, B. Vrijens, R. Eastell, C. Roux, H.A. Pols, J.D. Ringe, A. Grauer, D. Cahall, N.B. Watts, Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators, Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 92, 1296–1304 (2007)

    Article  CAS  PubMed  Google Scholar 

  14. R. Eastell, I. Barton, R.A. Hannon, A. Chines, P. Garnero, P.D. Delmas, Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J. Bone Miner. Res. 18, 1051–1056 (2003)

    Article  CAS  PubMed  Google Scholar 

  15. D.C. Bauer, D.M. Black, P. Garnero, M. Hochberg, S. Ott, J. Orloff, D.E. Thompson, S.K. Ewing, P.D. Delmas, Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J. Bone Miner. Res. 19, 1250–1258 (2004)

    Article  PubMed  Google Scholar 

  16. P.D. Delmas, F. Munoz, D.M. Black, F. Cosman, S. Boonen, N.B. Watts, D. Kendler, E.F. Eriksen, P.G. Mesenbrink, R. Eastell, The HORIZON-PFT Research Group, Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J. Bone Miner. Res. 24, 1544–1551 (2009)

    Article  CAS  PubMed  Google Scholar 

  17. P. Chen, J.H. Satterwhite, A.A. Licata, E.M. Lewiecki, A.A. Sipos, D.M. Misurski, R.B. Wagman, Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 20, 962–970 (2005)

    Article  CAS  PubMed  Google Scholar 

  18. E. Fink, C. Cormier, P. Steinmetz, C. Kindermans, Y. Le Bouc, J.C. Souberbielle, Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 1, 295–303 (2000)

    Article  Google Scholar 

  19. P. Bergmann, J.J. Body, S. Boonen, Y. Boutsen, J.P. Devogelaer, S. Goemaere, J.M. Kaufman, J.Y. Reginster, V. Gangji, Members of the Advisory Board on Bone Markers, Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int. J. Clin. Pract. 63, 19–26 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. R. Eastell, P. Garnero, C. Audebert, D. Cahall, Reference intervals of bone turnover markers in healthy premenopausal women: results from a cross-sectional European study. Bone 50(5), 1141–1147 (2012)

    Article  PubMed  Google Scholar 

  21. S.A. Chubb, C.D. Mandelt, S.D. Vasikaran, Comparison of results from commercial assays for plasma CTX: the need for harmonization. Clin. Biochem. 48, 519–524 (2015)

    Article  CAS  PubMed  Google Scholar 

  22. D.A. Eekman, I.E. Bultink, A.C. Heijboer, B.A. Dijkmans, W.F. Lems, Bone turnover is adequately suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC Musculoskelet. Disord. 12, 167 (2001)

    Article  Google Scholar 

  23. R. Eastell, B. Vrijens, D.L. Cahall, J.D. Ringe, P. Garnero, N.B. Watts, Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J. Bone Miner. Res. 26(7), 1662–1669 (2011)

    Article  CAS  PubMed  Google Scholar 

  24. S.A. Chubb, C. Mandelt, S. Vasikaran, Comparison of clinical cut-points and treatment targets for urine NTX and plasma βCTX-I in osteoporosis. Clin. Biochem. (2015). doi:10.1016/j.clinbiochem.2015.12.002

    Google Scholar 

  25. A.I. Sebba, S.L. Bonnick, R. Kagan, D.E. Thompson, C.S. Skalky, E. Chen, A.E. de Papp, Fosamax Actonel Comparison Trial Investigators, Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr. Med. Res. Opin. 20(12), 2031–2041 (2004)

    Article  CAS  PubMed  Google Scholar 

  26. K. Saag, R. Lindsay, A. Kriegman, E. Beamer, W. Zhou, A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 40(5), 1238–1243 (2007)

    Article  CAS  PubMed  Google Scholar 

  27. D.L. Kendler, C. Roux, C.L. Benhamou, J.P. Brown, M. Lillestol, S. Siddhanti, H.S. Man, J. San Martin, H.G. Bone, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J. Bone. Miner. Res. 25, 72–78 (2010)

    Article  CAS  PubMed  Google Scholar 

  28. R. Eastell, J.H. Krege, P. Chen, E.V. Glass, J.Y. Reginster, Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 22, 61–66 (2006)

    Article  CAS  PubMed  Google Scholar 

  29. M. Tsujimoto, P. Chen, A. Miyauchi, H. Sowa, J.H. Krege, PINP as an aid for monitoring patients treated with teriparatide. Bone 48, 798–803 (2009)

    Article  Google Scholar 

  30. D.C. Bauer, A. Schwartz, L. Palermo, J. Cauley, M. Hochberg, A. Santora, S.R. Cummings, D.M. Black, Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern. Med. 174(7), 1126–1134 (2014)

    Article  PubMed  PubMed Central  Google Scholar 

  31. R.E. Marx, J.E. Cill Jr, J.J. Ulloa, Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J. Oral Maxillofac. Surg. 65(12), 2397–2410 (2007)

    Article  PubMed  Google Scholar 

  32. S.L. Ruggiero, T.B. Dodson, J. Fantasia, R. Goodday, T. Aghaloo, B. Mehrotra, F. O’Ryan, American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw–2014 update. J. Oral Maxillofac. Surg. 72(10), 1938–1956 (2014)

    Article  PubMed  Google Scholar 

  33. A. Hutcheson, A. Cheng, R. Kunchar, B. Stein, P. Sambrook, A. Goss, A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: a prospective single-center controlled study. J. Oral Maxillofac. Surg. 72(8), 1456–1462 (2014)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Fiona Stanley Hospital, 102-118 Murdoch Drive, Murdoch, WA, 6150, Australia

    Samuel D. Vasikaran & S. A. Paul Chubb

  2. School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, WA, 6009, Australia

    Samuel D. Vasikaran & S. A. Paul Chubb

  3. School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA, 6009, Australia

    S. A. Paul Chubb

Authors
  1. Samuel D. Vasikaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. A. Paul Chubb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel D. Vasikaran.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vasikaran, S.D., Paul Chubb, S.A. The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis. Endocrine 52, 222–225 (2016). https://doi.org/10.1007/s12020-016-0900-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-016-0900-2

Keywords

Search

Navigation